Alto Neuroscience, Inc.

NYSE: ANRO · Healthcare · Biotechnology

PublicHQ Mountain View, CA · Santa ClaraCIK 0001999480Reports USD

#1 of 1,420 Healthcare companies by revenue

EA Score

——

FH 61DQ —GM —SS 48

v0.1 · 35/100 weight · pillars only

↑ Altman-Z, balance-sheet leverage · ↓ listing tenure, Piotroski F

Methodology →

Revenue TTM

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$63.2M

Employees

as of 2026-08-10

Market cap

$1.0B

as of 2026-08-10

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Net income-$63.2M-$63.2M2025

Operating income-$66.4M-$66.4M2025

Total assets$184.7M$184.7M2025

Liabilities$33.5M$33.5M2025

Equity$151.1M$151.1M2025

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

What is Alto Neuroscience, Inc.’s financial profile?

Alto Neuroscience, Inc. earned -$63.2M in FY2025 net income.

Peers · Healthcare

Seaport Therapeutics, Inc. Common Stock——Olema Pharmaceuticals, Inc.——Replimune Group, Inc.——Lumexa Imaging Holdings, Inc. Common Stock——Sana Biotechnology, Inc.——Annexon, Inc.——

Neighbors

Santa Clara →

NVIDIA Corporation$215.9B90A Apple Inc.$416.2B84B+Alphabet Inc.$402.8B81B+Broadcom Inc.$63.9B76B+Advanced Micro Devices, Inc.$34.6B78B+Cisco Systems, Inc.$56.7B85A

Key facts

CEOAmit Etkin

SectorHealthcare

IndustryBiotechnology

HeadquartersMountain View, CA

ExchangeNYSE: ANRO

Employees68

IPO date2024-02-02

Latest filings

8-K2026-08-27 10-Q2026-08-12 8-K2026-08-12 8-K2026-07-14 8-K2026-07-13 8-K2026-05-28 10-Q2026-05-13 8-K2026-05-13

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.